Rome IV - Functional Chest Pain

Why use it

Non-cardiac chest pain (NCCP) is among the most common presentations in emergency departments and cardiology clinics, accounting for 50–60% of all chest pain evaluations. After cardiac causes are excluded, a large proportion of patients have esophageal functional chest pain. Applying Rome IV B3 criteria provides a positive diagnosis, terminates unnecessary cardiac and gastroenterological investigations, enables earlier initiation of evidence-based treatment (neuromodulators, psychological therapy), reduces emergency department re-presentations, and addresses the significant burden of health anxiety and catastrophising that accompanies this condition. A positive diagnosis (rather than diagnosis of exclusion) has itself been shown to reduce anxiety and improve outcomes in patients with functional chest pain.

About

The Rome IV criteria for Functional Chest Pain (category B3) were established by the Rome Foundation Esophageal Disorders Committee and published in Gastroenterology in 2016. Functional Chest Pain of presumed esophageal origin is defined as recurrent midline chest pain or discomfort that is not of a burning quality, with no evidence that gastroesophageal reflux is responsible for the symptom, and absence of histopathology-based esophageal motility disorders, with criteria fulfilled for the last 3 months and symptom onset at least 6 months before diagnosis. This category represents the esophageal functional disorder in which the chest discomfort cannot be attributed to GERD (negative ambulatory pH-impedance monitoring, absence of symptom-reflux correlation), to an esophageal motility disorder with histopathological basis (achalasia, EoE-associated dysmotility), or to cardiac causes. Functional Chest Pain encompasses conditions previously described as non-cardiac chest pain (NCCP) of esophageal origin, nutcracker esophagus, and diffuse esophageal spasm without structural basis. Central sensitisation and visceral hypersensitivity are the dominant pathophysiological mechanisms — affected patients demonstrate lowered pain thresholds to esophageal balloon distension and acid perfusion. Psychological comorbidities (panic disorder, health anxiety, generalised anxiety disorder) are extremely common and are both causes and consequences of the condition. Functional chest pain affects 25–30% of patients presenting to emergency departments or cardiology clinics with chest pain, after cardiac causes are excluded.

When to use

• Adults with recurrent midline chest pain or discomfort after adequate cardiac evaluation has excluded coronary artery disease, aortic pathology, pericarditis, and other cardiac causes
• After GERD has been adequately excluded — empirical PPI trial followed by ambulatory pH-impedance monitoring if symptoms persist (or pH-impedance as first-line in patients already on PPI)
• After major esophageal motility disorders with structural basis (achalasia, eosinophilic esophagitis) have been excluded — high-resolution esophageal manometry and/or endoscopy as indicated
• In patients with chest pain who have had multiple negative cardiac evaluations and continue to present to emergency departments or cardiologists
• Patients with predominant chest pain in the context of panic disorder or health anxiety — functional chest pain is the gastroenterological diagnosis; concurrent psychological diagnosis should be made
• NOT to be used as the primary diagnostic framework before cardiac causes have been excluded — coronary artery disease must always be considered first
• NOT applicable when GERD is confirmed as the cause of chest pain on pH-impedance monitoring with positive symptom-reflux correlation

Formula

Pearls & pitfalls

• The single most important step before applying Rome IV B3 is adequate cardiac exclusion — never label chest pain as "functional" before appropriate cardiac evaluation in a patient with risk factors or atypical features.
• GERD must be rigorously excluded — a negative response to a PPI trial is NOT sufficient. Up to 30% of patients with confirmed reflux-related chest pain will not respond to empirical PPI. Ambulatory pH-impedance monitoring with symptom correlation is the gold standard.
• Rome IV B3 specifies that the chest pain is "not of burning quality" — burning chest pain should raise suspicion for reflux hypersensitivity (B2) or heartburn-predominant GERD, even if pH monitoring is negative.
• Visceral hypersensitivity is the central mechanism — patients with functional chest pain have a significantly lower pain threshold to esophageal balloon distension (approximately 50% lower than controls). This underpins the rationale for neuromodulators.
• Psychological comorbidity is extremely common — panic disorder occurs in approximately 30–50% of patients with functional chest pain. The chest pain of panic disorder is real, not fabricated, and is best understood as the esophageal manifestation of the panic response (esophageal spasm, visceral hypersensitivity during anxiety states).
• Tricyclic antidepressants (TCAs) work primarily via central and peripheral neuromodulation rather than antidepressant effect — the analgesic benefit occurs at doses (10–50 mg) well below antidepressant doses, and within 2–4 weeks. Explain this to patients to prevent self-discontinuation when they learn the medication is an "antidepressant."
• Health anxiety and cardiac hypervigilance must be directly addressed — patients often present repeatedly to emergency departments. Each presentation reinforces the anxiety cycle. Breaking this cycle (CBT, reassurance, neuromodulators) is as therapeutically important as treating the chest pain itself.
• High-resolution esophageal manometry (HRM) with Chicago Classification v4.0 categorises esophageal motility disorders — functional chest pain can only be diagnosed after HRM excludes achalasia, absent contractility, and other major motility disorders.
• Esophageal spasm on HRM (DES, hypercontractile esophagus / Jackhammer esophagus) without a histopathological basis does NOT disqualify a Rome IV B3 diagnosis — these manometric findings may coexist with functional chest pain and may represent a secondary manifestation of visceral hypersensitivity.
• The positive predictive value of a positive diagnosis — telling the patient they have a well-recognised, treatable condition with a clear pathophysiological explanation — has been shown in RCTs to reduce healthcare utilisation and improve quality of life, independent of specific treatment.

Next steps

Functional Chest Pain (Rome IV B3) confirmed: Explain the diagnosis — reassure that the heart is not the cause, but that the pain is real and originates from heightened sensitivity of the esophagus (visceral hypersensitivity). Avoid repeated cardiac investigations — these reinforce health anxiety without diagnostic benefit. First-line treatment: low-dose tricyclic antidepressants (amitriptyline 10–25 mg at night or imipramine 50 mg/day) — evidence from multiple RCTs shows significant pain reduction independent of antidepressant effect. Alternative: SSRIs (sertraline 50–200 mg, paroxetine 10–40 mg) with evidence from small RCTs — use when TCA is contraindicated or poorly tolerated. Psychotherapy: cognitive behavioural therapy (CBT) is effective and addresses health anxiety, pain catastrophising, and cardiac hypervigilance. Hypnotherapy (gut-directed) has evidence from RCTs. If psychological comorbidity is prominent (panic disorder, GAD): refer to psychiatry/psychology. Pain modulators: gabapentin or pregabalin may be considered in refractory cases (limited evidence). Esophageal-targeted therapy: adenosine receptor antagonist theophylline (limited evidence); calcium channel blockers (diltiazem) for spasm-type episodes. Criteria not met: ensure cardiac evaluation is complete (ECG, troponin, stress testing as indicated). Reassess GERD exclusion. If GERD not excluded: empirical double-dose PPI for 8 weeks followed by ambulatory pH-impedance monitoring. If motility not assessed: high-resolution esophageal manometry.

Evidence

Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders. Gastroenterology. 2016;150(6):1368-1379.e2. PMID:27144631. Primary Rome IV reference for B3 Functional Chest Pain. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17(2):110-123. PMID:21602987. Systematic review: Wang WH et al. Five percent dextrose infusion for non-cardiac chest pain: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2014. Clouse RE, Lustman PJ — landmark RCT showing imipramine 50 mg/day significantly reduced noncardiac chest pain vs placebo. Cannon RO — NCI study demonstrating visceral hypersensitivity to intracoronary adenosine in NCCP. Kachintorn U et al. How do we define non-cardiac chest pain? J Neurogastroenterol Motil. 2011;17(3):218-223.

References

1. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional Esophageal Disorders. Gastroenterology. 2016;150(6):1368-1379.e2. — link
2. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17(2):110-123. — link
3. Drossman DA (ed). Rome IV: Functional Gastrointestinal Disorders. 4th ed. Raleigh, NC: Rome Foundation; 2016. — link
4. Clouse RE, Lustman PJ, Eckert TC et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. Gastroenterology. 1987;92(4):1027-1036. — link
5. Pandolfino JE, Kahrilas PJ. New technologies in the gastrointestinal clinic and research: impedance and high-resolution manometry. Gastroenterology. 2008;135(4):1069-1078. — link